AVN-944
- CAS No.
- 501345-02-4
- Chemical Name:
- AVN-944
- Synonyms
- AVN-944;[(1s)-2-cyano-1-methyl-ethyl] N-[(1r)-1-[3-[(3-methoxy-4-oxazol-5 -yl-phenyl)carbamoylamino]phenyl]ethyl]carbamate
- CBNumber:
- CB82582988
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD22200574
- MOL File:
- Mol file
| Product description | Number | Pack Size | Price |
| (R)-1-CYANOPROPAN-2-YL(S)-1-(3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)PHENYL)ETHYL CARBAMATE 95.00% | BRS0000940 | 5MG | $497.57 |
| NCI Dictionary of Cancer Terms | AVN944 |
|---|---|
| FDA UNII | I3NPL1V48Q |
| NCI Drug Dictionary | AVN944 |
AVN-944 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| American Custom Chemicals Corporation | BRS0000940 | (R)-1-CYANOPROPAN-2-YL(S)-1-(3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)PHENYL)ETHYL CARBAMATE 95.00% | 501345-02-4 | 5MG | $497.57 | 2021-12-16 | Buy |
| Product number | Packaging | Price | Buy |
|---|---|---|---|
| BRS0000940 | 5MG | $497.57 | Buy |
AVN-944 Chemical Properties,Uses,Production
Uses
AVN-944 is a novel inosine monophosphate dehydrogenase (IMPDH) inhibitor. It has antiproliferative effects and might be combined with other agents for treatment of human prostate cancer.This compound is suitable for pyruvate dehydrogenase (PDH) related research.
Enzyme inhibitor
This orally available antineoplastic agent (FW = 310.36 g/mol; CAS 297730-17-7), also known as VX-944 and (R) -1-cyanobutan-2-yl- (S) -1- (3- (3- (3-methoxy-4- (oxazol-5-yl) phenyl) ureido) phenyl) ethyl) carbamate, inhibits inosine 5’-monophosphate dehydrogenase (IMPDH), the enzyme catalyzing the conversion of IMP into XMP, leading to the biosynthesis of GMP, GDP, GTP, and ultimately dGTP. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies, and AVN944 appears to have a selective cytotoxic effect on cancer cells. Reduction of GTP in normal cells results in a temporary slowing of cell growth only. AVN944 treatment results in dose-dependent cell growth inhibition in all studied prostate cancer cells, independently of their androgen sensitivity . AVN944 treatment arrests LNCaP cells in G1-phase and and androgen- independent 22Rv1, DU145 and PC-3 cells in S-phase. AVN-944 treatment leads to the rapid disappearance of nucleostemin, a positive regulator of cell proliferation that is highly expressed in a variety of stem cells, tumors, and tumor cell lines.
AVN-944 Preparation Products And Raw materials
Raw materials
Preparation Products
AVN-944 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131885 | 58 |
| Shanghai Boyle Chemical Co., Ltd. | 021-50182298 021-50180596 | sales@boylechem.com | China | 2203 | 55 |
| Changzhou Chenhong Biotechnology Co., Ltd. | +86-0519-85788828 +86-13775037613 | sales@chemrenpharm.com | China | 4049 | 58 |
| Shanghai Zeye Biotechnology Co., Ltd. | 021-57896695 13122364865 | sale1@shzysw.net | China | 9777 | 58 |
| Cayman Chemical Company | -- | sales@caymanchem.com | China | 6808 | 58 |
| Guangzhou Yiran Biotechnology Co., Ltd. | -- | CHINA | 6841 | 58 |
